INT141452

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.41
Pain Relevance 3.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (ABAT)
Anatomy Link Frequency
cerebral cortex 2
ABAT (Homo sapiens)
Pain Link Frequency Relevance Heat
gABA 180 100.00 Very High Very High Very High
analgesia 8 99.60 Very High Very High Very High
tricyclic antidepressant 1 99.08 Very High Very High Very High
agonist 16 97.94 Very High Very High Very High
intrathecal 5 97.40 Very High Very High Very High
cerebral cortex 1 97.20 Very High Very High Very High
central pain 20 96.46 Very High Very High Very High
antagonist 2 94.96 High High
allodynia 1 94.12 High High
Hyperalgesia 1 93.56 High High
Disease Link Frequency Relevance Heat
Schizophrenia 32 97.48 Very High Very High Very High
Pain 29 96.46 Very High Very High Very High
Neuropathic Pain 1 94.12 High High
Hyperalgesia 1 93.56 High High
Cognitive Disorder 1 87.04 High High
INFLAMMATION 1 71.68 Quite High
Injury 1 70.24 Quite High
Stroke 1 69.16 Quite High
Suicidal Behaviour 2 61.52 Quite High
Intractable Pain 1 56.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For example, laboratory evidence has generally supported the ability of GABA to reduce dopaminergic activity, and has suggested that GABA may be effective in combating hypofrontality by acting on the mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs.12,13 As a result, it has been claimed by some investigators that it might be possible to decrease negative symptoms and cognitive impairment in people with schizophrenia by treatment with glutamatergic drugs.13
Negative_regulation (reduce) of GABA Binding (ability) of associated with cognitive disorder, gaba and schizophrenia
1) Confidence 0.37 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987504 Disease Relevance 0.40 Pain Relevance 0.33
1) Clinical reports of central pain relief after the administration of intrathecal baclofen, a GABA-B agonist.2–6 2) Clinical trials in which tricyclic antidepressant therapy produce analgesia presumably through reversal of GABA inhibition.7 3) Laboratory reports in animals in which application of GABA in the cerebral cortex produced analgesia and intrathecal GABA antagonists produced allodynia and hyperalgesia.8
Negative_regulation (reversal) of GABA Binding (inhibition.7) of in cerebral cortex associated with pain, central pain, allodynia, tricyclic antidepressant, analgesia, gaba, hyperalgesia, antagonist, agonist, cerebral cortex and intrathecal
2) Confidence 0.33 Published 2010 Journal Perspect Medicin Chem Section Body Doc Link PMC2918363 Disease Relevance 0.93 Pain Relevance 1.89
Consistent with previous observations, thiocolchicoside also inhibited the binding of GABA to rat cerebral cortical membranes.
Negative_regulation (inhibited) of GABA Binding (binding) of associated with gaba
3) Confidence 0.21 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17234181 Disease Relevance 0.07 Pain Relevance 0.44
3 subunit receptors display a reduced sensitivity to GABA, which has been traced to an extracellular N-terminal domain of four amino acids within the ?
Negative_regulation (reduced) of GABA Binding (sensitivity) of associated with gaba
4) Confidence 0.05 Published 2006 Journal BMC Pharmacol Section Body Doc Link PMC1363348 Disease Relevance 0 Pain Relevance 0.51

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox